SiBone (NASDAQ:SIBN) and OrthoPediatrics (NASDAQ:KIDS) Critical Analysis

OrthoPediatrics (NASDAQ:KIDS – Get Free Report) and SiBone (NASDAQ:SIBN – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for OrthoPediatrics and SiBone, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OrthoPediatrics 1 1 7 0 2.67
SiBone 1 0 7 0 2.75

OrthoPediatrics presently has a consensus price target of $33.88, indicating a potential upside of 6.78%. SiBone has a consensus price target of $25.00, indicating a potential upside of 5.35%. Given OrthoPediatrics’ higher probable upside, equities research analysts plainly believe OrthoPediatrics is more favorable than SiBone.

Valuation and Earnings

This table compares OrthoPediatrics and SiBone”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OrthoPediatrics $236.35 million 3.50 -$39.65 million ($1.43) -22.19
SiBone $200.93 million 5.33 -$18.90 million ($0.31) -76.55

SiBone has lower revenue, but higher earnings than OrthoPediatrics. SiBone is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

OrthoPediatrics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, SiBone has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

Insider & Institutional Ownership

69.1% of OrthoPediatrics shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 32.5% of OrthoPediatrics shares are held by insiders. Comparatively, 4.0% of SiBone shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares OrthoPediatrics and SiBone’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OrthoPediatrics -12.83% -8.10% -5.46%
SiBone -6.20% -7.57% -5.55%

Summary

SiBone beats OrthoPediatrics on 7 of the 13 factors compared between the two stocks.

About OrthoPediatrics

(Get Free Report)

OrthoPediatrics Corp. develops and markets orthopedic implants and instruments designed specifically for children and adolescents. Its products support surgeons treating a range of pediatric conditions, including fractures, spinal deformities, limb-length differences and other orthopedic disorders. The company’s portfolio includes systems for trauma and deformity correction, scoliosis treatment, limb lengthening and external fixation, as well as specialized surgical instruments. It also provides related education and support for pediatric orthopedic surgeons and care teams.

About SiBone

(Get Free Report)

SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.

Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.